Biocon Biologics gets credit boost from S&P, outlook stable

The rating on senior secured notes issued by Biocon Biologics Global PLC was also upgraded to ‘BB+.’

Wanbury unveils API facility in Tanuku, targets Rs. 100 crore revenue

The Tanuku facility will focus on the production of key therapeutic APIs, including Anti-Tussive, Anti-Coagulant (Blood Thinner), Anaesthetic, and Antidepressant molecules

Thyrocare posts strong Q3FY26 results: revenue up 18%, PAT soars 47%

Vimta Labs reports 10% YoY growth in Q3 FY26, PAT margins hold at 17.5%

The company reported Q3 total income of Rs. 1,005 million, marking a 10.2% increase year-on-year

Vetter to invest €480 million in major German manufacturing expansion, eyes 2,000 jobs

The state-of-the-art commercial production plant will be built on a 95-acre site in Saarlouis, acquired at the end of 2024

Moderna teams up with Recordati to commercialize rare disease therapy

Siegfried expands US footprint with major acquisition of Noramco & Extractas Bioscience

The deal brings three high-quality small-molecule drug substance sites into Siegfried’s portfolio

Lonza posts CHF 6.5 billion in 2025 sales, marks strong profit growth

Excluding Vacaville-related business, organic CER sales growth reached the low-teens with improved CORE EBITDA margins, in line with Lonza’s CDMO Organic Growth Model

Fides launches imaging CRO focused on early-phase clinical decision-making

Fid?s brings core strengths across imaging applications and human biology, supporting work in digestive disease, GI oncology, and select solid tumors

Will Forte joins Teva Pharmaceuticals to shine spotlight on Huntington’s disease

HD causes cognitive, behavioral, and physical challenges, including involuntary movements known as HD chorea, which can disrupt daily life